Key result
Elevated platelets linked to ~214% higher death and major disability risk in high HS-CRP stroke patients.
Why the study?
It was unknown whether the relationship between baseline platelet count and clinical outcomes is modulated by HS-CRP in patients with ischemic stroke.
Does elevated baseline platelet count increase the risk of adverse clinical outcomes in patients with ischemic stroke, and is this modified by HS-CRP levels?
Observational (n=3,267)
Does elevated baseline platelet count increase the risk of adverse clinical outcomes in patients with ischemic stroke, and is this modified by HS-CRP levels?
Effect estimate: OR 3.14 (95% CI 1.77-5.58)
p-value: p=<0.05
Elevated platelet count is associated with adverse clinical outcomes after ischemic stroke specifically in patients with high HS-CRP levels, suggesting a synergistic effect of inflammation and platelet activation.
No takes yet. Share an insight, caveat, or question.
May refine post-stroke prognosis in high-inflammation patients; hypothesis-generating and requires prospective validation.
Liu et al. (2023) conducted an observational in Ischemic stroke (n=3,267). Elevated platelet count vs. Lower platelet count was evaluated on Combination of death and major disability at 1 year after ischemic stroke (OR 3.14, 95% CI 1.77-5.58, p=<0.05). Elevated platelet count was significantly associated with death and major disability at 1 year in ischemic stroke patients with high HS-CRP levels (OR 3.14; 95% CI 1.77-5.58).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: